Guggenheim Capital LLC Sells 6,428 Shares of Novo Nordisk A/S (NYSE:NVO)

Guggenheim Capital LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 22.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,119 shares of the company's stock after selling 6,428 shares during the period. Guggenheim Capital LLC's holdings in Novo Nordisk A/S were worth $1,903,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Center for Financial Planning Inc. increased its stake in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Albion Financial Group UT raised its stake in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock valued at $44,000 after buying an additional 278 shares during the period. Hager Investment Management Services LLC bought a new position in shares of Novo Nordisk A/S during the 4th quarter worth approximately $46,000. Sound Income Strategies LLC increased its holdings in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock worth $46,000 after acquiring an additional 243 shares during the last quarter. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in Novo Nordisk A/S in the 4th quarter valued at $47,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the subject of a number of recent research reports. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. UBS Group upgraded shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and a consensus price target of $135.00.

Novo Nordisk A/S Trading Up 1.8 %

NYSE:NVO traded up $1.09 during trading hours on Thursday, hitting $62.39. 3,696,809 shares of the company were exchanged, compared to its average volume of 6,052,927. The company has a fifty day simple moving average of $74.34 and a 200 day simple moving average of $90.56. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The stock has a market capitalization of $280.00 billion, a price-to-earnings ratio of 18.95, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a dividend of $0.7874 per share. The ex-dividend date of this dividend was Monday, March 31st. This represents a yield of 1.2%. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.